These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 29742281)

  • 1. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
    Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
    Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic potential in advanced cancer patients.
    Nichols D; Arnold S; Weiss HL; Wu J; Durbin EB; Miller R; Kolesar J
    Am J Health Syst Pharm; 2019 Mar; 76(7):415-423. PubMed ID: 31361818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
    Kaufman AL; Spitz J; Jacobs M; Sorrentino M; Yuen S; Danahey K; Saner D; Klein TE; Altman RB; Ratain MJ; O'Donnell PH
    Mayo Clin Proc; 2015 Jun; 90(6):716-29. PubMed ID: 26046407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.
    Borden BA; Jhun EH; Danahey K; Schierer E; Apfelbaum JL; Anitescu M; Knoebel R; Shahul S; Truong TM; Ratain MJ; O'Donnell PH
    Pharmacogenomics J; 2021 Dec; 21(6):691-711. PubMed ID: 34376788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
    O'Donnell PH; Ratain MJ
    Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
    Nagy M; Attya M; Patrinos GP
    Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes.
    Hutchcraft ML; Lin N; Zhang S; Sears C; Zacholski K; Belcher EA; Durbin EB; Villano JL; Cavnar MJ; Arnold SM; Ueland FR; Kolesar JM
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
    Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
    Quaranta S; Thomas F
    Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.
    Reid P; Danahey K; Lopez Velazquez M; Ratain MJ; O'Donnell PH
    Clin Exp Rheumatol; 2021; 39(6):1385-1393. PubMed ID: 33506753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
    Hafner S; Haubensak S; Paul T; Zolk O
    Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
    [No Abstract]   [Full Text] [Related]  

  • 14. Modern developments in germline pharmacogenomics for oncology prescribing.
    Reizine NM; O'Donnell PH
    CA Cancer J Clin; 2022 Jul; 72(4):315-332. PubMed ID: 35302652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka.
    Ranasinghe P; Sirisena N; Vishnukanthan T; Ariadurai JN; Thilakarathne S; Priyadarshani CDN; Bhagya Hendalage DP; Dissanayake VHW
    BMC Med Genomics; 2024 May; 17(1):143. PubMed ID: 38789983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
    Tsaousis GN; Papadopoulou E; Agiannitopoulos K; Pepe G; Tsoulos N; Boukovinas I; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Kapsimalis A; Xepapadakis G; Psyrri A; Banu E; Eniu DT; Blidaru A; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
    Cancer Genomics Proteomics; 2022; 19(1):60-78. PubMed ID: 34949660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.